Arcutis Biotherapeutics logo

Arcutis BiotherapeuticsNASDAQ: ARQT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

31 January 2020

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$999.42 M
-38%vs. 3y high
73%vs. sector
-vs. 3y high
-vs. sector
-63%vs. 3y high
83%vs. sector
-99%vs. 3y high
69%vs. sector

Price

after hours | Fri, 01 Nov 2024 21:17:46 GMT
$8.55+$0.27(+3.26%)

Dividend

No data over the past 3 years
$30.86 M$37.62 M
$30.86 M-$52.33 M

Analysts recommendations

Institutional Ownership

ARQT Latest News

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
zacks.com25 October 2024 Sentiment: NEGATIVE

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
globenewswire.com18 October 2024 Sentiment: POSITIVE

ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two decades1 Second approval of ZORYVE outside of the United States, expanding ZORYVE portfolio availability to over 2 million Canadians living with seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that its wholly-owned subsidiary Arcutis Canada, Inc. has received regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis in patients 9 years of age and older.

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
globenewswire.com25 September 2024 Sentiment: POSITIVE

ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin type ZORYVE was safe and well tolerated across all subgroups Data presented at the 2024 European Academy of Dermatology & Venereology Congress WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology and immunology, today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials showing that ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of AD in individuals regardless of race, ethnicity, and Fitzpatrick skin types.

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
globenewswire.com24 September 2024 Sentiment: POSITIVE

U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025 Almost half of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp Supplemental New Drug Application (sNDA) supported by positive efficacy and safety data from Phase 2b and pivotal Phase 3 trials, and long-term ZORYVE cream plaque psoriasis program WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3%, a once-daily, next generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis.

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
seekingalpha.com22 August 2024 Sentiment: POSITIVE

Arcutis Biotherapeutics, Inc. is a biotech company based in California that markets two dermatological products, ZORYVE cream and foam, containing roflumilast, a PDE4 inhibitor. Despite initial struggles post-IPO, Arcutis has seen a significant increase in revenues and a narrowing of losses in Q2 2024, with new product approvals and collaborations. Analysts predict strong growth potential for ZORYVE, but competition in the dermatological market poses a challenge for Arcutis to maintain and grow market share.

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript
seekingalpha.com15 August 2024 Sentiment: NEUTRAL

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Latha Vairavan - VP, Finance and Head of IR Frank Watanabe - President & CEO Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - CFO Conference Call Participants Vikram Purohit - Morgan Stanley Tyler Van Buren - TD Cowen Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Securities Serge Belanger - Needham Chris Shibutani - Goldman Sachs Operator Hello, and thank you for standing by. Welcome to Arcutis Biotherapeutics Q2 2024 Earnings Call.

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates
zacks.com14 August 2024 Sentiment: NEUTRAL

Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $1.16 per share a year ago.

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
zacks.com07 August 2024 Sentiment: NEGATIVE

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
globenewswire.com29 July 2024 Sentiment: POSITIVE

Over 200-person sales force to promote ZORYVE (roflumilast) in primary care and pediatric practices Provides access to a large portion of the 7.4 million individuals treated for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis outside of dermatology offices ZORYVE will be promoted in the primary position to maximize prescriber education WESTLAKE VILLAGE, Calif. and MONTGOMERY, Ala.

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
globenewswire.com29 July 2024 Sentiment: POSITIVE

Once-daily, effective, safe, and well-tolerated ZORYVE cream now commercially available Provides rapid clearance of atopic dermatitis signs and symptoms and significant reduction in itch, and can be used anywhere on the body for any duration to maintain clear skin Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United States Management will host an investor event with a key opinion leader on Monday, July 29 at 8:30 am EDT/5:30 am PDT WESTLAKE VILLAGE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age 6 in the United States.

  • 1(current)
  • 2
  • 3

What type of business is Arcutis Biotherapeutics?

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for dermatological diseases. The company was previously known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Our company is headquartered in Westlake Village, California. The company has a broad portfolio of drugs with significant potential for treating immune-mediated dermatological diseases and conditions. The company's lead product candidate is ARQ-151, a cream with roflumilast for the treatment of plaque psoriasis. The company is also developing ARQ-154, a roflumilast foam formulation for topical use to treat seborrheic dermatitis and scalp psoriasis. ARQ-252, a selective topical Janus kinase type 1 inhibitor for the treatment of chronic hand eczema and vitiligo. ARQ-255, a local formulation of ARQ-252, developed for deeper penetration into the skin to treat focal alopecia.

What sector is Arcutis Biotherapeutics in?

Arcutis Biotherapeutics is in the Healthcare sector

What industry is Arcutis Biotherapeutics in?

Arcutis Biotherapeutics is in the Biotechnology industry

What country is Arcutis Biotherapeutics from?

Arcutis Biotherapeutics is headquartered in United States

When did Arcutis Biotherapeutics go public?

Arcutis Biotherapeutics initial public offering (IPO) was on 31 January 2020

What is Arcutis Biotherapeutics website?

https://www.arcutis.com

Is Arcutis Biotherapeutics in the S&P 500?

No, Arcutis Biotherapeutics is not included in the S&P 500 index

Is Arcutis Biotherapeutics in the NASDAQ 100?

No, Arcutis Biotherapeutics is not included in the NASDAQ 100 index

Is Arcutis Biotherapeutics in the Dow Jones?

No, Arcutis Biotherapeutics is not included in the Dow Jones index

When was Arcutis Biotherapeutics the previous earnings report?

No data

When does Arcutis Biotherapeutics earnings report?

The next expected earnings date for Arcutis Biotherapeutics is 06 November 2024